Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Colorectal Neoplasms 3Skin Neoplasms 2Melanoma 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Turcot syndrome 1Solid Tumors 1Solid Tumor, Adult 1Rectal Neoplasms 1Radiation Pneumonitis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1NSCLC 1Motor Activity 1Lung Neoplasms 1Locally Advanced Esophageal Squamous Cell Carcinoma 1Kidney Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

testosterone 17 beta-cypionate 1Urinary Diversion 1Testosterone Propionate 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Cystectomy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urologic Diseases × Immune Checkpoint Inhibitors × Clear all
NCT05241340 2025-10-24

RAD-VACCINE

The Methodist Hospital Research Institute

Phase 2 Active not recruiting
33 enrolled
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡